Skip to content


NHT has assembled a highly qualified and experienced team to develop the first drug/device therapy product utilizing the DryNeb™ nebulizer. The company’s advisory board of comprises experienced pulmonary drug delivery experts who are knowledgeable in patient care, drug repurposing, drug formulation, device engineering, efficacy, and clinical trials – all important to the platform technology and drug/device product development.

The Executive Team

Board of Directors

    • Paul Atkins, PhD | Executive Chairman
    • Yun Li, PhD | CEO
    • Calvin Goforth, PhD | Director

Advisors and Consultants

    • John Pritchard, PhD | Chair of NHT Advisory Board
    • Charles L. Daly, MD | Chief, Division of Mycobaterial and Respiratory Infections, National Jewish Health, Denver. Colorado